New Trials – Crohn’s Disease & Ulcerative Colitis

NYGA is pleased to announce its participation in two clinical trials for patients with Crohn’s disease and ulcerative colitis. Both trials involve the evaluation of new oral medications. The drugs are developed by Landos Biopharma, Inc., and the BT-11-202B trial is being conducted in collaboration with researchers in the gastroenterology division of the Icahn School of Medicine at Mount Sinai.

Clinical trials are carefully organized and follow many procedures and regulations. These trials are intended to help determine whether the drugs are safe and effective for treating or preventing diseases.

There are advantages and risks associated with clinical trials. Prior to participating we recommend that you speak with your physician. Participating in a clinical trial is a personal decision and you always have the choice to change your mind and withdraw from the study.

If you are interested in learning more about the clinical trial contact our Research Coordinator, Salitah Qureshi, at 347-248-8719 or